AB50,1465,5 (4) Exceptions. (a) This section does not apply to a manufacturer that shows to the commissioner’s satisfaction that the manufacturer’s annual gross revenue from insulin sales in this state does not exceed $2,000,000.

AB50,1465,10 (b) A manufacturer may not be required to make an insulin product available under sub. (2) or (3) if the wholesale acquisition cost of the insulin product does not exceed $8, as adjusted annually based on the U.S. consumer price index for all urban consumers, U.S. city average, per milliliter or the applicable national council for prescription drug programs’ plan billing unit.

AB50,1465,13 (5) Confidentiality. All medical information solicited or obtained by any person under this section shall be subject to the applicable provisions of state law relating to confidentiality of medical information, including s. 610.70.

AB50,1465,19 (6) Reimbursement prohibition. No person, including a manufacturer, pharmacy, pharmacist, or 3rd-party administrator, as part of participating in an urgent need safety net program or patient assistance program may request or seek, or cause another person to request or seek, any reimbursement or other compensation for which payment may be made in whole or in part under a federal health care program, as defined in 42 USC 1320a-7b (f).

AB50,1465,22 (7) Reports. (a) Annually, no later than March 1, each manufacturer shall report to the commissioner all of the following information for the previous calendar year:

AB50,1466,2 1. The number of individuals who received insulin under the manufacturer’s urgent need safety net program.

AB50,1466,5 2. The number of individuals who sought assistance under the manufacturer’s patient assistance program and the number of individuals who were determined to be ineligible under sub. (3) (c) 4.

AB50,1466,7 3. The wholesale acquisition cost of the insulin provided by the manufacturer through the urgent need safety net program and patient assistance program.

AB50,1466,11 (b) Annually, no later than April 1, the commissioner shall submit to the governor and the chief clerk of each house of the legislature, for distribution to the legislature under s. 13.172 (2), a report on the urgent need safety net programs and patient assistance programs that includes all of the following:

AB50,1466,12 1. The information provided to the commissioner under par. (a).

AB50,1466,14 2. The penalties assessed under sub. (9) during the previous calendar year, including the name of the manufacturer and amount of the penalty.

AB50,1466,19 (8) Additional responsibilities of commissioner. (a) Application form. The commissioner shall make the application form described in sub. (2) (c) 1. a. available on the office’s website and shall make the form available to pharmacies and health care providers who prescribe or dispense insulin, hospital emergency departments, urgent care clinics, and community health clinics.

AB50,1466,22 (b) Public outreach. 1. The commissioner shall conduct public outreach to create awareness of the urgent need safety net programs and patient assistance programs.

AB50,1467,2 2. The commissioner shall develop and make available on the office’s website an information sheet that contains all of the following information:

AB50,1467,4 a. A description of how to access insulin through an urgent need safety net program.

AB50,1467,6 b. A description of how to access insulin through a patient assistance program.

AB50,1467,8 c. Information on how to contact a navigator for assistance in accessing insulin through an urgent need safety net program or patient assistance program.

AB50,1467,10 d. Information on how to contact the commissioner if a manufacturer determines that an individual is not eligible for a patient assistance program.

AB50,1467,12 e. A notification that an individual may contact the commissioner for more information or assistance in accessing ongoing affordable insulin options.

AB50,1467,19 (c) Navigators. The commissioner shall develop a training program to provide navigators with information and the resources necessary to assist individuals in accessing appropriate long-term insulin options. The commissioner shall compile a list of navigators that have completed the training program and are available to assist individuals in accessing affordable insulin coverage options. The list shall be made available on the office’s website and to pharmacies and health care practitioners who dispense and prescribe insulin.

AB50,1468,2 (d) Satisfaction surveys. 1. The commissioner shall develop and conduct a satisfaction survey of individuals who have accessed insulin through urgent need safety net programs and patient assistance programs. The survey shall ask whether the individual is still in need of a long-term solution for affordable insulin and shall include questions about the individual’s satisfaction with all of the following, if applicable:

AB50,1468,3 a. Accessibility to urgent-need insulin.

AB50,1468,5 b. Adequacy of the information sheet and list of navigators received from the pharmacy.

AB50,1468,6 c. Helpfulness of a navigator.

AB50,1468,8 d. Ease of access in applying for a patient assistance program and receiving insulin from the pharmacy under the patient assistance program.

AB50,1468,12 2. The commissioner shall develop and conduct a satisfaction survey of pharmacies that have dispensed insulin through urgent need safety net programs and patient assistance programs. The survey shall include questions about the pharmacy’s satisfaction with all of the following, if applicable:

AB50,1468,14 a. Timeliness of reimbursement from manufacturers for insulin dispensed by the pharmacy under urgent need safety net programs.

AB50,1468,15 b. Ease in submitting insulin orders to manufacturers.

AB50,1468,16 c. Timeliness of receiving insulin orders from manufacturers.